Online inquiry

IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12987MR)

This product GTTS-WQ12987MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12987MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2906MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ3782MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ3958MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ9700MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ10711MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ15150MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ10439MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ12453MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NKTR-214
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW